Back to Atlas
CTransientStandard research/education caution
CMP-0368
Approved in EU historically; investigational oncology
Lasofoxifene
Endocrine / SERM
Osteoporosis and ER-mutant breast-cancer research positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- SERM
- Primary mechanism
- Estrogen receptor modulation with bone/breast activity
- Primary market use
- Bone health / oncology
Pharmacology
- Molecular weight (Da)
- 413.94
- Oral bioavailability
- Oral
- Half-life
- ~6 d
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/Clinical
- Clinical status
- Approved in EU historically; investigational oncology
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Long half-life and potency, but limited current market availability